FAQ on Oragenics Inc.'s 1-for-30 Reverse Stock Split

What is a reverse stock split and how does it work?

A reverse stock split consolidates the number of existing shares into fewer, proportionally more valuable shares. In this case, Oragenics is consolidating every 30 shares into one to boost the share price.

When will the reverse stock split take effect?

The reverse stock split is set to take effect on June 3, 2025, with shares beginning to trade on a split-adjusted basis under the existing symbol ‘OGEN’ from that date.

Why is Oragenics implementing a reverse stock split?

The reverse stock split aims to increase the company’s share price to make it more appealing to long-term investors and enhance its capital markets profile, as stated by CEO Janet Huffman.

Will the reverse stock split affect the company’s stock symbol or CUSIP number?

The stock will continue to trade under the existing symbol ‘OGEN’, but a new CUSIP number will be assigned post-split.

What is Oragenics’ focus as a biotechnology company?

Oragenics is focused on the nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including treatments for mild traumatic brain injury (mTBI) and Niemann Pick Disease Type C (NPC).

Where can I find more information about Oragenics and its reverse stock split?

More information can be found on the company’s website at www.Oragenics.com or in the full press release available at https://ibn.fm/b5BaM.

The latest news and updates relating to OGEN are available in the company’s newsroom at https://ibn.fm/OGEN.

What are the implications of this reverse stock split for current shareholders?

Current shareholders will see their number of shares reduced by a factor of 30, but the value of each share will increase proportionally, maintaining the total value of their investment.

Summary